SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Cell Therapeutics (CTIC)
An SI Board Since August 1997
Posts SubjectMarks Bans Symbol
946 45 0 CTIC
Emcee:  Regis McConnell Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
371ok, need help in deciphering the Da Vinci Code here (in addition to zeta's rquidditch-1/9/2005
370Thanks Dave for taking care.. Zetazeta1961-1/8/2005
369I think xyotax is a slam dunk replacement for paclitaxel. It's likely going Natashya_Fatale-1/8/2005
368So basically if either Xyotax or pix gets approved before Jan 1, 2007, Bianco piBiomaven-1/6/2005
367Item 1.01. Entry Into a Material Definitive Agreement. [He still cannot afford Icebrg-1/6/2005
366Pixantrone, A New Anthracycline with Possibly Less Cardiotoxicity [Pixantrone mIcebrg-1/6/2005
365>> The researchers also note that seven of the eight patients who were bclscaram(o)uche-1/4/2005
364Rituximab plus CHOP slows follicular NHL Posted: January 04, 2005(From ASCzeta1961-1/4/2005
363Cell Therapeutics, Inc. (CTI) Licenses Lisofylline and Related Patent Portfolio Icebrg-1/4/2005
362Cell Therapeutics, Inc. (CTI) Licenses Lisofylline and Related Patent Portfolio nigel bates-1/4/2005
361Thank youtom pope-12/21/2004
360Currently a 2-year window on shelf registrations. The SEC has proposed changingFiloF-12/21/2004
359Hope you're right, otherwise the Feuerstein spin sounds plausible - althoughtom pope-12/21/2004
358They sold another 2 million dollars worth of stock today. Maybe there is some trIcebrg-12/21/2004
357Feuerstein on the new share sale: thestreet.comRocky9-12/21/2004
356some of the high implied volatility in the option premiums may represent the martom r. phillips-12/21/2004
355Cell Therapeutics, Inc. and Quintiles PharmaBio Development Enter Into TRISENOX(nigel bates-12/21/2004
354Why are the March call options still so high? With the news on the results delaRocky9-12/20/2004
353The marketing decision will, according to Bianco, be depending on what type of lIcebrg-12/20/2004
352Well, now we know why Bianco has been trumpeting the Stellar data ad nauseum latformer_pgs-12/20/2004
351Two and a half million additional shares will not matter much when there are aboIcebrg-12/20/2004
350Good negotiators.tom pope-12/20/2004
349Cell Therapeutics, Inc. Announces $18.4 Million Direct Equity Placement Monday DIcebrg-12/20/2004
348Encouraging Survival Estimates in Non-Small Cell Lung Cancer Push XYOTAX(TM) PivIcebrg-12/16/2004
347What's the point of a stock award if they have to sell shares to pay for therkrw-12/15/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News